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Hepatitis C
Antibodies among
Blood Donors,
Senegal, 2001
To the Editor: Prevalence of
chronic hepatitis C virus (HCV)
among blood donors has been
assessed in a few West African coun-
tries; most recent estimates range
from 1.1% to 6.7% (1–4). A recent
meta-analysis of studies, including a
confirmation test, yielded an average
prevalence of HCV infection of 3.0%
(5). Until 2001, no systematic screen-
ing of HCV infection occurred among
blood donors in Senegal, and blood
donation legislation is still pending.
We report an assessment of the pro-
portion of blood donors from the
Hôpital Principal de Dakar who had
HCV antibodies in 2001. 
Blood donors were all volunteers,
recruited independently from the hos-
pitalized patients and registered in a
local donors association. We screened
for risk factors for bloodborne infec-
tions in potential donors through a
clinical examination and a confiden-
tial questionnaire. Persons with a his-
tory of jaundice or a risk behavior
were excluded. Serum samples col-
lected from blood donors from June to
December 2001 were screened for
HCV antibodies by a third-generation
enzyme immunoassay (EIA) (HCV
Murex 4.0; Abbott Laboratories,
Abbott, IL). Confirmation was per-
formed by a recombinant-immunoblot
assay (INNO-LIAHCVAb III update;
[Innogenetics, Gent, Belgium]). HCV
RNA was detected by a qualitative
reverse transcription–polymerase
chain reaction (Roche Amplicor HCV
test [Hoffman-LaRoche, Basel,
Switzerland]). Genotype was deter-
mined by the INNO-LiPA HCV II
assay (Innogenetics). Presence of hep-
atitis B surface antigen (HbsAg) and
alanine-aminotransferase (ALAT)
level are routinely assessed, as well as
HIV and human T-lymphotropic virus
type l infection.
The age of the 1,081 donors
ranged from 18 years to 61 years
(mean 35.6 years), and 81% were
men. First-time donors accounted for
31% and were younger than repeat
donors (mean 30.5 years vs. 37.8
years; p < 10–4). EIA HCV antibodies
were found in 18 donors (1.6%).
Immunoblot assay was positive for
nine, yielding an overall prevalence of
0.8% (exact 95% confidence interval
0.4% to 1.5%). Eight of the nine were
repeat donors, but the difference in
prevalence compared with first-time
donors did not reach statistical signif-
icance (1.1% vs. 0.3%). HCV-infected
donors tended to be older than unin-
fected donors (mean 42.3 years vs.
35.5 years, median 46.7 years vs. 34.6
years, Mann-Whitney test p = 0.04),
and the trend with age was significant
(18–29 years 0.3%; 30–39 years
0.6%; 40–49 years 1.5%; >50 years
1.8%; chi-square trend = 4.39; p =
0.03). ALAT levels of infected study
participants were in the normal range
(17–55 IU). One participant had an
ALAT level above normal. Genotype
2ac has been identified on line
immunoassay–positive samples (three
samples not tested). HBsAg was
detected in 13% of the new donors.
No co-infection with HCV and hepa-
titis B virus was found.
The prevalence of HCV antibodies
in blood donors in Dakar in 2001
appears to be one of the lowest in
West Africa, close to published esti-
mates for Mauritania and Benin (1.1%
and 1.4%, respectively) and lower
than in other West African countries
such as Ghana or Guinea, where
prevalence ranges from 2.8% to 6.7%
(1–4). This finding is in keeping with
results of a hospital case-control study
on HCV infection and liver cirrhosis
or cancer, conducted in 1995 in
Dakar. While that study did not iden-
tify HCV infection in 73 controls, 2 of
73 case-patients (2.7%) had HCV
antibodies (6). Conversely, high HCV
prevalence was found in groups at
risk: antibodies were present in 12 of
15 hemodialysis patients, and HCV
RNA was found in 6 of the 12 HVC
antibody-positive patients (genotype
2ac, the same as in our study); 7% of
a cohort of 58 HIV-1 patients receiv-
ing highly active antiretroviral thera-
py had a positive HCV serologic
result (7,8). 
In the urban setting of Dakar, HCV
infection seems still to be confined to
groups at risk. The contribution of
HCV to chronic liver diseases has not
been yet demonstrated. Approx-
imately 15,000 blood donations are
annually made in Dakar. A systematic
screening of HCV antibodies in blood
donors could prevent, on average, 120
bloodborne HCV infections each year.
Given these data and the price of EIA
and LIA, the screening cost per HCV-
positive sample identified, and infec-
tion subsequently averted, is approxi-
mately 200,300 CFA(U.S.$305). This
estimate is low since it includes only
the marginal cost of the reagent kits.
This screening cost could be reduced
by discarding blood units that test
positive after only one enzyme-linked
immunosorbent assay (156,000 CFA
or U.S.$237), at the price of nearly
3% of blood units wrongly discarded.
France has demonstrated that this
strategy has the best cost-effective-
ness ratio, as long as the prevalence
remains below 8% (9). This cost com-
pares favorably with the cost per HIV
infection averted through improve-
ment of blood safety (range
U.S.$20–U.S.$1,000), assessed in
some highly HIV-prevalent southern
African countries (Tanzania, Zambia,
Zimbabwe) (10). The HCV-positive
discarded blood units will be added to
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the blood units testing positive for
hepatitis B surface (13%), HIV, and
HTLV, which accounted for nearly
one third of all donations in 2001.
These findings argue in favor of main-
taining a roster of regular, seronega-
tive donors to save numbers of blood
units. 
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Prosthetic Valve
Endocarditis due to
Kytococcus
schroeteri
To the Editor: Bacteria belonging
to the former genus Micrococcus, the
so-called micrococci, are usually
regarded as contaminants from skin
and mucous membranes. Neverthe-
less, micrococci have been reported as
emerging pathogens in immunocom-
promised patients and have been
described in severe infections (1–4).
We describe what is, to our knowl-
edge, the first case of prosthetic valve
endocarditis caused by the newly
described micrococcal species,
Kytococcus schroeteri. Accurate iden-
tification of this species is of particu-
lar importance as kytococci—in con-
trast to other micrococcal species—
are frequently resistant to penicillin
and oxacillin (5).
A 34-year-old woman was admit-
ted to the hospital with acute, severe
aortic regurgitation, attributable to a
dissection of both the ascending and
descending aorta, which extended into
the supraaortic and iliac arteries.
Immediate surgical intervention was
performed by implantation of an aor-
tic arch (St. Jude Medical Inc., St.
Paul, MN) conduit and reimplantation
of the supraaortic arteries. Ten weeks
later, the patient was admitted to the
hospital because of fever of 39°C.
Laboratory studies showed a leuko-
cyte count of 15.3 x 109/L with 87%
neutrophils and elevated C-reactive
protein (180 mg/L). Transesophageal
echocardiography and computed
tomography suggested an abscess
next to the prosthesis and showed
vegetations on the prosthetic valve,
which suggested endocarditis. Blood
cultures yielded gram-positive cocci
on four separate occasions during an
11-day period. Treatment, performed
according to the antimicrobial suscep-
tibilities of the isolates, consisted of
vancomycin, gentamicin, and
rifampin for 21 days. Within 1 week,
the fever resolved and the leukocyte
count returned to normal. Four days
after antimicrobial therapy was initi-
ated, right-sided hemiparesis and
aphasia, thought to be due to an
embolic cerebral stroke, developed.
After those events, the aortic arch
prosthesis was replaced without fur-
ther complications.
Blood culture specimens were
injected into BACTEC Plus culture
vials for aerobic and anaerobic cul-
tures and processed in BACTEC 9240
blood culture system (Becton
Dickinson, Cockeysville, MD).
Growth was detected in four different
aerobic blood cultures after incubation
of 3 to 5 days. Aerobic subcultures on
Columbia agar supplemented with 5%
sheep blood showed tiny, muddy-yel-
low colonies without hemolysis after
24 h of incubation. After 48 h, the size
of colonies increased, a feature typical
of K. sedentarius, which is known to
grow slightly more slowly than other
members of the former Micrococcus
genus. No or very weak reactions
were found after 24 h incubation when
the ID32 STAPH ATB gallery
(bioMérieux Vitek, Hazelwood, MO)
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